aTYR PHARMA (ATYR) Cash & Equivalents (2014 - 2026)

aTYR PHARMA (ATYR) has reported Cash & Equivalents for 13 consecutive years, with $16.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Equivalents fell 6.16% year-over-year to $16.2 million; the trailing twelve-month figure through Jun 2026 stood at $16.2 million (down 6.16% YoY), and the FY2025 full-year result was $10.7 million, down 2.82% from the prior year.
• Cash & Equivalents advanced to $16.2 million in Q2 2026 per ATYR's latest filing, from $10.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $22.5 million in Q4 2023 and bottomed at $6.1 million in Q3 2025.
• Historically, Cash & Equivalents has averaged $12.1 million across 5 years, with a median of $10.6 million in 2025.
• The widest YoY moves for Cash & Equivalents: up 327.27% in 2022, down 69.27% in 2022.
• Over 5 years, Cash & Equivalents stood at $10.0 million in 2022, then jumped by 125.87% to $22.5 million in 2023, then slumped by 50.96% to $11.1 million in 2024, then declined by 2.82% to $10.7 million in 2025, then soared by 50.42% to $16.2 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $16.2 million, $10.0 million, and $10.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.